Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab self-administration crossover study in generalized myasthenia gravis
jRCT2021230009Completed
- Sponsor
- UCB
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of rozanolixizumab in myasthenia gravis (MG) (2 arms), sponsored by UCB. Primary endpoints: Successful self-administration at Visit 13 and Successful self-administration at Visit 19. Started Jun 2023; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2021230009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230009.